TY - JOUR
T1 - Gene therapy for retinal and choroidal diseases
AU - Campochiaro, Peter A.
N1 - Funding Information:
There are several diseases of the retina and choroid for which gene therapy-based treatments hold promise. Recent success Supported by grants EY05951, EY10017, EY09769, EY11279 and core grant P30EY1765 from the National Eye Institute, a Lew R Wasserman Merit Award and unrestricted funds from Research to Prevent Blindness, a grant from Dr and Mrs W Lake, a grant from M Pannitch and a grant from the Steinbach Foundation. PAC is the George S and Dolores Dore Eccles Professor of Ophthalmology.
PY - 2002
Y1 - 2002
N2 - The eye is a small compartment separated from the systemic circulation by the blood-ocular barriers, providing advantages for intraocular gene transfer - an approach which is being investigated for several types of retinal and choroidal diseases. A compelling application is gene replacement for homozygous loss-of-function mutations in genes differentially expressed in photoreceptors or retinal pigmented epithelial (RPE) cells that result in retinal degeneration. Considerable progress has been made in this area, including demonstration of return of visual function in RPE65-/- dogs after subretinal injection of adeno-associated viral vectors encoding RPE65, providing groundwork for a clinical trial in patients with Leber's Congenital Amaurosis. Proof of principle has been provided for intraocular gene transfer of ribozymes for dominantly inherited retinal degenerations. Survival factor gene therapy shows promise for treatments that may be used in multiple retinal degenerations. Transduction of intraocular and/or periocular cells with constructs that encode antiangiogenic proteins provides a new approach for sustained local delivery treatment of retinal and choroidal neovascularisation. While considerable investigation remains to work out critical details, there is substantial evidence suggesting that in the near future, gene therapy-based treatments will be an important addition to what is currently offered to patients with retinal and/or choroidal diseases.
AB - The eye is a small compartment separated from the systemic circulation by the blood-ocular barriers, providing advantages for intraocular gene transfer - an approach which is being investigated for several types of retinal and choroidal diseases. A compelling application is gene replacement for homozygous loss-of-function mutations in genes differentially expressed in photoreceptors or retinal pigmented epithelial (RPE) cells that result in retinal degeneration. Considerable progress has been made in this area, including demonstration of return of visual function in RPE65-/- dogs after subretinal injection of adeno-associated viral vectors encoding RPE65, providing groundwork for a clinical trial in patients with Leber's Congenital Amaurosis. Proof of principle has been provided for intraocular gene transfer of ribozymes for dominantly inherited retinal degenerations. Survival factor gene therapy shows promise for treatments that may be used in multiple retinal degenerations. Transduction of intraocular and/or periocular cells with constructs that encode antiangiogenic proteins provides a new approach for sustained local delivery treatment of retinal and choroidal neovascularisation. While considerable investigation remains to work out critical details, there is substantial evidence suggesting that in the near future, gene therapy-based treatments will be an important addition to what is currently offered to patients with retinal and/or choroidal diseases.
KW - Gene therapy
KW - Neovascularisation
KW - Neurotrophic factors
KW - Proliferative retinopathies
KW - Retinal degenerations
UR - http://www.scopus.com/inward/record.url?scp=0035987409&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035987409&partnerID=8YFLogxK
U2 - 10.1517/14712598.2.5.537
DO - 10.1517/14712598.2.5.537
M3 - Review article
C2 - 12079489
AN - SCOPUS:0035987409
SN - 1471-2598
VL - 2
SP - 537
EP - 544
JO - Expert Opinion on Biological Therapy
JF - Expert Opinion on Biological Therapy
IS - 5
ER -